Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, life-threatening acquired genetic disorder that causes the premature destruction of red blood cells. Though named for a historical symptom – dark urine appearing at night – the condition is far more complex. The underlying problem is a mutation affecting blood cell production, leading to a cascade of complications including severe anemia, debilitating fatigue, and a significantly increased risk of dangerous blood clots.
What Causes PNH?
PNH develops when a spontaneous genetic mutation occurs in hematopoietic stem cells within the bone marrow. This mutation affects the PIGA gene, crucial for creating a protective shield around red blood cells. Without this shield, the immune system’s complement system attacks and destroys these cells prematurely, resulting in hemolysis – the breakdown of red blood cells. The mutation isn’t inherited; it appears after birth and isn’t passed down through families.
How Is PNH Diagnosed?
Diagnosis typically begins with recognizing symptoms consistent with red blood cell destruction, like unexplained fatigue, shortness of breath, and dark urine. A complete blood count (CBC) and basic metabolic panel can reveal abnormalities, prompting further investigation. Definitive diagnosis relies on flow cytometry, a specialized test that identifies the abnormal red blood cells characteristic of PNH. Earlier tests like the sucrose hemolysis and Ham tests were used historically but are less accurate.
Symptoms: Beyond Dark Urine
The symptoms of PNH vary widely, but key indicators include:
- Fatigue: Often severe and disabling.
- Hemolytic Anemia: Leading to shortness of breath, rapid heartbeat, and headaches.
- Blood Clots: A major risk, causing abdominal pain, difficulty breathing, or neurological issues.
- Esophageal Spasms: Severe pain when swallowing.
- Erectile Dysfunction: In men.
The historical connection to dark urine (“nocturnal” in PNH’s name) is unreliable: many patients never experience this symptom. Symptoms fluctuate, worsening during stress, infection, or trauma.
Treatment and Prognosis
PNH treatment has drastically improved in recent decades. Historically, the prognosis was grim – most patients died within 10-20 years of diagnosis. Today, with targeted therapies, life expectancy is comparable to that of healthy individuals.
Key treatments include:
- Eculizumab (Soliris): A monoclonal antibody that blocks the complement system.
- Ravulizumab (Ultomiris): A longer-acting alternative to Eculizumab.
- Pegcetacoplan (Empaveli): A newer therapy with a different mechanism of action.
These drugs significantly reduce red blood cell destruction, but patients require lifelong treatment and vaccinations against meningococcal infections due to immune suppression. Blood transfusions, growth factors (like erythropoietin), and in severe cases, bone marrow transplants remain options.
Risks and Complications
Untreated PNH can lead to:
- Severe Anemia: Requiring frequent transfusions.
- Blood Clots: Potentially fatal if they obstruct vital organs.
- Budd-Chiari Syndrome: Liver damage from obstructed hepatic veins.
- Chronic Kidney Disease: From hemoglobin overload.
Pregnancy is high-risk for PNH patients, with increased chances of blood clots, preeclampsia, and fetal complications.
Prevalence and Outlook
PNH affects approximately 0.5 to 1.5 per million people, though estimates vary. The condition is equally likely to occur in both sexes. While a cure remains elusive for most, modern treatments have transformed PNH from a rapidly fatal disease into a manageable chronic condition. Effective management relies on early diagnosis, continued therapy, and proactive monitoring for complications.
